Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease
09 December 2021 - 11:05PM
Business Wire
Forma SCD Trend Report: The State of Transition
survey reveals 62% of patients found the transition experience
“moderately or very challenging” and 73% of physicians state there
are a lack of transition guidelines and protocols in their practice
or institution
formabridge grants will support programs and
research initiatives to address unmet needs in transition from
pediatric to adult care in sickle cell disease
New transition resource hub www.formabridge.com
for patients and caregivers launched at the 63rd American Society
of Hematology Annual Meeting and Exposition
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a
clinical-stage biopharmaceutical company focused on sickle cell
disease (SCD), prostate cancer and other rare hematologic diseases
and cancers, today announced formabridge. Through formabridge
grants, Forma has committed $1M in funding for promising and
innovative initiatives that address unmet needs in transition from
pediatric to adult care in SCD. Funding will be provided to
researchers, healthcare institutions, patient and community
organizations based on specific criteria. Proposals will be
reviewed by a panel of Forma personnel and external advisors with
expertise in the challenges impacting transition in SCD. Grants
will be awarded to proposals that have the greatest potential to
improve patient care in the first half of 2022.
“We’ve been moved by our discussions with the SCD community,
particularly as we learn more about how patients experience the
disease as they age out of the pediatric system,” said Frank Lee,
president and chief executive officer of Forma. “Though great
strides have been made to reduce pediatric mortality and morbidity
in SCD, the period of transition leads to significant care gaps,
and sadly is often marked by increased hospitalizations and
mortality. Successful transition will require a collective and
concerted effort to change the future of SCD. Our hope is that
formabridge will play an impactful role in securing a safer and
healthier future for people living with this disease.”
Forma’s inaugural SCD Trend Report: The State of Transition
provides insights from a robust survey of patients, caregivers and
physicians. The report highlights obstacles patients face during
transition and identifies areas where patients and physicians have
differing views. The report will be published annually and is
intended to facilitate discussion on opportunities to better
support people living with SCD, along with opportunities to support
key systemic and policy changes. Key findings in the report
include:
- 62% of patients found their overall transition experience
“moderately or very challenging”
- 78% of patients report discrimination and stigma prevent them
from receiving the SCD care they need
- 73% of physicians agree there is a lack of transition
guidelines and protocols in their practice or institution
“Increasing the understanding of challenges faced by both
patients and health care providers during transition from pediatric
to adult care is fundamental to fixing the problem,” said Dr.
Nirmish Shah, a hematologist and the director of the Sickle Cell
Transition Program at Duke University. “While there are no
immediate or easy answers, my hope is that funding and other
resources from formabridge can help to move the needle for people
living with SCD.”
www.formabridge.com is intended to serve as a resource hub for
patients during transition. Through collaboration with patient
advocacy groups throughout the United States, the site offers
educational, credible and actionable information to help the
community navigate Medicaid, disability benefits, and more, and is
curated for easy access and understanding. The site also includes
inspirational educational videos to engage and support patients
during the transition process.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company
focused on the research, development and commercialization of novel
therapeutics to transform the lives of patients with rare
hematologic diseases and cancers. Our R&D engine combines deep
biology insight, chemistry expertise and clinical development
capabilities to create drug candidates with differentiated
mechanisms of action focused on indications with high unmet need.
Our work has generated a broad proprietary portfolio of programs
with the potential to provide profound patient benefit. For more
information, please visit www.FormaTherapeutics.com or follow us on
Twitter @FORMAInc and LinkedIn.
Forward-looking Statements
This press release may contain forward-looking statements and
information within the meaning of the Private Securities Litigation
Reform Act of 1995 and other federal securities laws. The use of
words such as “may,” “will,” “could,” “would,” “should,” “expects,”
“intends,” “plans,” “anticipates,” “believes,” “estimates,”
“predicts,” “projects,” “seeks,” “endeavors,” “potential,”
“continue,” “target” or the negative of such words or other similar
expressions can be used to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. The express or implied forward-looking
statements included in this press release, including the potential
benefit and impact of formabridge on sickle cell disease patients,
are only predictions and are subject to a number of risks,
uncertainties and assumptions, including, without limitation risks
set forth under the caption “Risk Factors” in Forma’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2021, as
well as other risks detailed in our subsequent filings with the
Securities and Exchange Commission. In light of these risks,
uncertainties and assumptions, the forward-looking events and
circumstances discussed in this press release may not occur and
actual results could differ materially and adversely from those
anticipated or implied in the forward-looking statements. You
should not rely upon forward-looking statements as predictions of
future events. Although Forma believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot guarantee that the future results, levels of activity,
performance or events and circumstances reflected in the
forward-looking statements will be achieved or occur. Moreover,
except as required by law, neither Forma nor any other person
assumes responsibility for the accuracy and completeness of the
forward-looking statements included in this press release. Any
forward-looking statement included in this press release represents
Forma’s views only as of the date on which it was made. Forma
undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211209005353/en/
Media: Adam Silverstein, +1 917-697-9313 Porter Novelli
adam.silverstein@porternovelli.com
Investor: Mario Corso, +1 781-366-5726 Forma Therapeutics
mcorso@formatherapeutics.com
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Aug 2023 to Aug 2024